Compare AU
Compare DRUG vs. ACDC
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare Currency Hedged ETF (DRUG) and the Global X Battery Tech & Lithium ETF (ACDC). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | ACDC | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 61 | 2,323 |
Median incremental investment | $920.50 | $802.32 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $1,310.55 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | ACDC | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | The Global X Battery Tech & Lithium ETF (ASX: ACDC) seeks to track the performance of The Solactive Global Lithium Index before account fees, expenses and taxes. The index invests in companies involved in the lithium business. This includes companies involved in all aspects of lithium, from mining and refining the metal, to producing batteries and Electric Vehicles (EVs). |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Tesla Inc (5.48 %) Eos Energy Enterprises Inc Ordinary Shares Class A (4.70 %) Sumitomo Electric Industries Ltd (3.81 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Consumer Discretionary (44.06 %) Industrials (38.02 %) Information Technology (17.92 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | Japan (23.82 %) United States (18.30 %) Korea (13.38 %) |
Management fee | 0.57 % | 0.69 % |
Key Summary
DRUG | ACDC | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Solactive Battery Value-Chain Index |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.69 % |
Price | $7.95 | $87.37 |
Size | $185.172 million | $511.858 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 4.05 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 03/09/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | ACDC | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 61 | 2,323 |
Median incremental investment | $920.50 | $802.32 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $1,310.55 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | ACDC | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | ACDC |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |